Valuation: BLS Pharmaceuticals Limited

Market Cap 213M 148M 130M 120M 110M 210M 14.13B 1.43B 561M 6.96B 556M 544M 23.94B P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 207M 144M 126M 116M 107M 204M 13.73B 1.39B 545M 6.76B 540M 529M 23.25B EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
44.73%
Yield 2024 *
-
Yield 2025 -
1 day+11.11%
1 week-4.26%
Current month-3.23%
1 month+4.65%
3 months+36.36%
6 months+136.84%
Current year+114.29%
1 week 0.76
Extreme 0.76
0.97
1 month 0.76
Extreme 0.76
1.1
Current year 0.36
Extreme 0.36
1.1
1 year 0.33
Extreme 0.33
1.1
3 years 0.04
Extreme 0.04
1.1
5 years 0.04
Extreme 0.04
1.1
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Date Insider Type Main position Quantity % Market Cap.
14/05Buy 5,000,000 0.2202%
14/05Fiscal year 5,000,000 0.2202%
22/03Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
+11.11%-4.26%+119.51%+462.50% 144M
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average +0.71%-0.75%+71.37%+139.76% 24.41B
Weighted average by Cap. -0.48%-0.23%+80.72%+124.53%

Financials

2024 2025
Net sales 9.64M 6.71M 5.87M 5.41M 5M 9.48M 640M 64.65M 25.39M 315M 25.18M 24.63M 1.08B 29.28M 20.37M 17.81M 16.43M 15.18M 28.8M 1.94B 196M 77.1M 957M 76.47M 74.8M 3.29B
Net income -13.33M -9.27M -8.11M -7.48M -6.91M -13.1M -884M -89.35M -35.09M -435M -34.8M -34.04M -1.5B 4.9M 3.41M 2.98M 2.75M 2.54M 4.82M 325M 32.86M 12.91M 160M 12.8M 12.52M 551M
Net Debt -318K -221K -193K -178K -165K -312K -21.07M -2.13M -836K -10.38M -829K -811K -35.68M -6.13M -4.27M -3.73M -3.44M -3.18M -6.03M -407M -41.13M -16.15M -200M -16.02M -15.67M -689M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
10/07/26 $0.9000 +11.11% 561,579
09/07/26 $0.8100 0.00% 672,668
08/07/26 $0.8100 -12.90% 432,841
07/07/26 $0.9300 0.00% 78,843
06/07/26 $0.9300 -1.06% 343,953

Annual profits - Rate of surprise